Abstract:The PI3K/AKT/mTOR signalling pathway is one of the most frequently activated pathways in breast cancer and also plays a central role in the regulation of several physiologic functions. There are major efforts ongoing to exploit precision medicine by developing inhibitors that target the three kinases (PI3K, AKT, and mTOR). Although multiple compounds have been developed, at present, there are just three inhibitors approved to target this pathway in patients with advanced ER-positive, HER2-negative breast cancer: everolimus (mTOR inhibitor), alpelisib (PIK3CA inhibitor), and capivasertib (AKT inhibitor). Like most targeted cancer drugs, resistance poses a major problem in the clinical setting and is a factor that has frequently limited the overall efficacy of these agents. Drug resistance can be categorised into intrinsic or acquired resistance depending on the timeframe it has developed within. Whereas intrinsic resistance exists prior to a specific treatment, acquired resistance is induced by a therapy. The majority of patients with ER-positive, HER2-negative advanced breast cancer will likely be offered an inhibitor of the PI3K/AKT/mTOR pathway at some point in their cancer journey, with the options available depending on the approval criteria in place and the cancer's mutation status. Within this large cohort of patients, it is likely that most will develop resistance at some point, which makes this an area of interest and an unmet need at present. Herein, we review the common mechanisms of resistance to agents that target the PI3K/AKT/mTOR signalling pathway, elaborate on current management approaches, and discuss ongoing clinical trials attempting to mitigate this significant issue. We highlight the need for additional studies into AKT1 inhibitor resistance in particular.

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects

The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

PI3K/AKT signaling pathway and cancer: an updated review

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer

The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer

Targeting the PI3K pathway in cancer: are we making headway?

Targeting PI3K in cancer: mechanisms and advances in clinical trials

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Targeting PI3K/Akt/mTOR Signaling in Cancer

PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review

Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer